Haleon plc (NYSE:HLN) Shares Bought by Whittier Trust Co. of Nevada Inc.

Whittier Trust Co. of Nevada Inc. raised its position in Haleon plc (NYSE:HLN) by 66.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,192 shares of the company’s stock after buying an additional 3,678 shares during the quarter. Whittier Trust Co. of Nevada Inc.’s holdings in Haleon were worth $97,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the company. Cultivar Capital Inc. acquired a new stake in Haleon during the 2nd quarter worth $40,000. Allspring Global Investments Holdings LLC acquired a new stake in shares of Haleon during the first quarter worth about $43,000. Pinnacle Bancorp Inc. grew its holdings in shares of Haleon by 29.8% during the first quarter. Pinnacle Bancorp Inc. now owns 6,188 shares of the company’s stock worth $53,000 after buying an additional 1,421 shares during the last quarter. Hexagon Capital Partners LLC increased its position in Haleon by 66.6% in the 2nd quarter. Hexagon Capital Partners LLC now owns 6,695 shares of the company’s stock valued at $55,000 after acquiring an additional 2,677 shares during the period. Finally, BOKF NA raised its stake in Haleon by 68.8% during the 2nd quarter. BOKF NA now owns 6,972 shares of the company’s stock valued at $58,000 after acquiring an additional 2,842 shares during the last quarter. 6.67% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently issued reports on HLN shares. The Goldman Sachs Group lowered Haleon from a “buy” rating to a “neutral” rating in a report on Tuesday, August 6th. Morgan Stanley boosted their price objective on shares of Haleon from $9.90 to $10.95 and gave the company an “overweight” rating in a research note on Friday, September 20th. UBS Group upgraded shares of Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. Finally, Berenberg Bank began coverage on shares of Haleon in a report on Tuesday, August 6th. They issued a “buy” rating on the stock. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $10.95.

Haleon Trading Down 0.2 %

Shares of HLN stock opened at $9.90 on Thursday. The business’s fifty day moving average price is $10.23 and its 200 day moving average price is $9.18. The firm has a market capitalization of $45.18 billion, a PE ratio of 32.98, a P/E/G ratio of 2.93 and a beta of 0.26. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. Haleon plc has a 1-year low of $7.70 and a 1-year high of $10.80.

Haleon (NYSE:HLN) last announced its quarterly earnings results on Thursday, August 1st. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The company had revenue of $3.50 billion during the quarter, compared to analysts’ expectations of $3.55 billion. Haleon had a net margin of 9.71% and a return on equity of 13.15%. During the same quarter in the prior year, the business earned $0.08 EPS. As a group, sell-side analysts forecast that Haleon plc will post 0.47 EPS for the current fiscal year.

Haleon Cuts Dividend

The company also recently declared a semi-annual dividend, which was paid on Thursday, September 19th. Investors of record on Friday, August 16th were issued a $0.0514 dividend. This represents a dividend yield of 1.6%. The ex-dividend date was Friday, August 16th. Haleon’s dividend payout ratio is currently 33.33%.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.